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Abstract:  46 
Aim: The determinants of serum vitamin D seems to be environmental factors (dietary and 47 
supplementary intake and exposure to ultraviolet light) and genetic factors. We aimed to study the 48 
relationship between a vitamin D-associated genetic polymorphism and serum 25(OH)D 49 
concentrations in healthy adolescent girls in Iran, and its effects on a high dose supplement of 50 
vitamin D.  51 
Material and method: A total of 616 healthy adolescent girls with mean age 15 received 50000 IU 52 
of vitamin D3 weekly over 9 weeks. Serum vitamin D levels and other metabolic factors were 53 
measured at baseline and after the intervention. The genotyping of the CYP2R1 variant 54 
(rs10741657) was performed by TaqMan genotyping assays.  55 
Results: Regardless of genetic background, at baseline, 87% of adolescent girls were vitamin D 56 
deficient (serum 25(OH)D level<50nmol/l). High-dose supplementation with VitD reduced the 57 
proportion of girls who were deficient substantially to about 24%. Genetic analysis revealed that 58 
although at baseline there was not a gene-vitamin D association (P trend=0.1), the response to 59 
supplementation appeared to be modulated by this variant (P trend<0.001). However, other 60 
anthropometric and biochemical measures were not affected by this intervention, over this short 61 
period. Serum 25(OH)D was increased in all participants although the carriers of the minor A 62 
allele seemed to be better responders so that the percentages of change serum vitamin D in the 63 
holder of AA and AG genotypes were 539.4±443.1and 443.7±384.6 respectively, compared to 64 
those with common GG genotype (363.3±354.0). Our regression analysis revealed that the 65 
probability of an increase in serum 25(OH)D in a participant with AA genotype was 2.5 fold 66 
greater than those with a GG genotype (OR=2.5 (1.4-4.4); p value=0.002). 67 
Conclusion: Based on our findings, it appears that the rs10741657 variant of the CYP2R1 gene 68 
modulates the response to high-dose of vitamin D supplementation. 69 
Keywords: CYP2R1, rs10741657, vitamin D, supplementation 70 
 71 
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 73 
Introduction 74 
In human, the main sources of vitamin D are cutaneous synthesis and diet although it is influenced 75 
by other environmental factors including environmental factors and genetic background vitamin D 76 
can be synthetize by either the skin, or through dietary intake, such as fatty fish, egg yolk, some 77 
mushrooms. Meanwhile, the ultraviolet irradiance at northern latitudes is too low to produce 78 
enough vitamin D over the winter season; therefore, the fortified foods with vitamin D and 79 
supplements have been the effective ways to receive adequate vitamin D1..Since the diet source of 80 
vitamin D is rare, fortified foods with vitamin D and supplements have been the effective ways to 81 
receive adequate vitamin D 2. However, Vitamin D deficiency is a widespread public health 82 
problem globally. This issue is related to clinical complications such as autoimmune diseases, 83 
various cancers, obesity, cardiovascular disorders, and metabolic syndrome and even pregnancy 84 
outcome. Currently, serum 25-hydroxyvitamin D concentrations have been used to determine 85 
vitamin D status, but due to lack of the accuracy in the diagnostic essay and the lack of reference 86 
standard, this bio-factor is under questioned.  However, the scientists cannot yet reach a consensus 87 
on the healthy range of serum 25-hydroxyvitamin D concentrations in various population groups. 88 
Growing bodies of evidence suggested the influences of environmental and genetic background on 89 
vitamin D variation in people. Some studies have reported an inverse association between body 90 
mass index (BMI) and variation in serum 25(OH)D level 3, 4, suggesting volumetric dilution, 91 
storage of vitD and up-regulation of the vitamin D receptor (VDR) in the adipose tissue might lead 92 
to lower response to vitamin D intake in obese people4, 5 ; however, the results have been 93 
controversial6, 7. Moreover, An age-related reduction in renal faction and also calcium absorption 94 
leads to declining in 1,25(OH)2D8, 9.On the other hand, studies on twins and their families have 95 
revealed heritability of the serum vitamin D levels. Additionally, emerging evidence has studied 96 
the genetic locus related to this hormone. Recently, several genetic determinants of circulating 97 
vitamin D have been suggested, including Gc, CYP2R1 and CYP24A1, VDR, DHCR1 10. 98 
CYP2R1 accounts for the hydroxylation of vitamin D in the first stage of vitamin D activation11 99 
and researchers have attached importance to gene variants regarding vitamin D status 10, 12, 13. The 100 
current study was carried out to determine the potential effect of the rs10741657 polymorphism 101 
located on chromosome 11p15.2, in terms of responding to high-dose vitamin D supplementation 102 
in 616 healthy Iranian girls suffering from vitamin D deficiency. 103 
Material and method 104 
Study population 105 
A cohort of 616 adolescent girls, with average age 15 years old, were recruited by a randomized 106 
cluster sampling method14. The study ran between January and April 2015 in Mashhad city, and 107 
consent forms were filled by all participants according to protocols approved by the Ethics 108 
Committee of the Mashhad University of Medical Sciences. The exclusion criteria were a history 109 
of the various chronic disease, receiving any kind of dietary supplementation, anti-depressant or 110 
psychotropic drugs. Subjects received 50,000 IU vitamin D/week for 9 weeks.  111 
Anthropometric and biochemical measurements 112 
Various anthropometric parameters including height (cm), body weight (kg) as described before. 113 
Moreover, biochemical factors; serum high sensitivity C-reactive protein (Hs-CRP), fasting blood 114 
glucose (FBG) and lipid profile; total cholesterol (TC), triglyceride (TG), high-density lipoprotein 115 
cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C), Serum calcium (Ca), 116 
phosphate (P) were evaluated 15-17. Serum 25(OH) vitamin D level was measured using an 117 
electrochemi-luminescence method (ECL, Roche, Basel, Switzerland). (%). We categorized serum 118 
25 (OH) D status as deficient for serum 25(OH)D level <50 nmol/l, sufficient for a serum 25(OH) 119 
D level between 50 to 75 nmol/l, and proposed optimal group with serum 25(OH)D level > 75 120 
nmol/l. All measurements were done at baseline and following 9 weeks of intervention17. 121 
DNA extraction and genotyping 122 
Genomic DNA was extracted from blood samples using a QIAamp® DNA Mini-Kit (Qiagen, San 123 
Diego, CA) following the manufacturer's instructions. The purity and concentration of DNA 124 
samples were determined using the NanoDrop®-1000-Detector (NanoDrop-Technologies, 125 
Wilmington, USA). Genotyping analysis of CYP2R1-rs10741657 polymorphism was carried out 126 
using a Taq-man®-probes-based assay; PCR reactions were performed in 12.5 ml total volume, 127 
using 20 ng of DNA in TaqMan®n Universal MasterMix with specific primers and probes 128 
(Applied Biosystems Foster City, CA).  We re-genotyped 10 per cent of samples, resulting in 129 
100% reproducibility. The allelic content was evaluated using the ABIPRISM-7500 instrument 130 
with the SDS version-2.0 software.  131 
Statistics analysis 132 
Normally distributed variables were reported as the mean ± standard deviation (SD), and non-133 
parametric data was shown as median (Q3-Q1). The Kolmogorov–Smirnov test was performed for 134 
the analysis of the normality of continuous variables. We also did an analysis of variance 135 
(ANOVA) to compare changes in biomarkers after intervention in different genotypic groups. Post 136 
hoc analysis was done using Tukey’s test. A Chi-square test with continuity correction was used to 137 
determine whether genotype frequencies followed the Hardy–Weinberg Equilibrium. Moreover, to 138 
investigate the effect of the genotypes, repeated measures analysis of covariance (ANCOVA) was 139 
used, together with a logistic regression model, we examined the probability of changes in serum 140 
25(OH) D in various genetic models. Data were analyzed using SPSS version 20, IBM (SPSS Inc., 141 
IL, USA), and significance was set at p < 0.05.                                                                                                                           142 
Results 143 
Influences of supplementation on circulation 25(OH) D in the total population, regardless of the 144 
genetic make-up  145 
A shown in Figure 1, at baseline, the serum vitamin D in about 87% of the studied population was 146 
<50nmol/L (vitamin D deficient), with approximately 19% and 6% in the vitamin D sufficient and 147 
proposed optimal categories, respectively. The proportion of individuals categorized as deficient 148 
fell sharply after supplementation with high-dose of vitamin D, to approximately 20%. On the 149 
other hand, the share of subjects having vitamin D at sufficient levels increased by about 13%. On 150 
supplementation, the percentage of girls with a proposed optimal level of vitamin D increased to 151 
60.5%. It is noteworthy that in total population mean±SD of serum 25(OH)D before 152 
supplementation was 26.2±23.7 mg/dl and after supplementation became 90.0±42.2 mg/dl 153 
Influences of supplementation on circulation 25(OH) D in CYP2R1 variant  154 
 155 
To examine the influence of CYP2R1 variant on the circulation levels of vitamin D after the 156 
intervention, subjects were categorized by rs10741657 genotype. There was no significant trend in 157 
the distribution of vitamin D status (proposed optimal, sufficiency and deficiency) among different 158 
genotypes at baseline (P-trend = 0.1). However, supplementation for 9 weeks led to a significant 159 
trend (P-trend =0.001) (Table 1), with a reduction in the percentage of subjects with a low serum 160 
vitamin D. It appeared that responding to the serum 25 (OH) D was dependent on the genotype at 161 
the CYP1 locus (Fig. 2); during the supplementation, serum (OH) D increased in all groups, but 162 
carriers who had the common A allele, had higher vitamin D concentrations. Perhaps the SNP 163 
rs10741657 modulated response to vitamin D supplementation (p-value of intervention 164 
effect=0.001 and p-value of SNP effect=0.006) (Fig. 2). The results of the regression analysis also 165 
showed that in the additive model, the probability of increasing serum 25(OH)D, in individuals 166 
who had the homozygous genotype AA was two and a half fold higher than those who were 167 
homozygous for the common GG genotype (OR=2.5 (1.4-4.4); p value=0.002). The regression 168 
model was also significant using a recessive model (OR=1.65 (1.1-2.4); p value=0.008) and 169 
dominant model (OR=2.05 (1.2-3.4); p value=0.007) (Table 3). Data was adjusted for potential 170 
confounders such as age, BMI, and season.  171 
Influence of supplementation on metabolic profile in CYP2R1 variant 172 
Further analysis showed that changes in various clinical and anthropometrics measures after 173 
intervention were not variant-dependent which meant that neither at baseline nor after the 174 
intervention, we could not see any difference among carriers of different genotypes (table 2). 175 
However, individuals possessing an uncommon “A” allele were better responder to 176 
supplementation than those with GG genotype in terms of serum 25(OH) D; the percentage of 177 
changes in serum 25(OH) D for participants with GG, AG, and AA genotypes were 363.3±354, 178 
443.7±384.6 and 539.4±443.1 respectively (P value (GG vs AA/AG)=0.003).  179 
Discussion 180 
The purpose of the current study was to investigate whether a specific variant at the CYP2R1 locus 181 
on chromosome 11p15.2 was associated with an altered response to high-dose of vitamin D 182 
supplementation. Although at baseline, the distribution of individuals with different genotypes was 183 
not statistically significant in different vitamin D groups, after the intervention, the changes in 184 
serum 25 (OH)D did appear to be influenced by this variant. Our data showed that holders of less 185 
common variant might be a better responder to vitamin D supplementation. The logistic model also 186 
demonstrated that the likelihood of increase in serum 25(OH)D in the homozygotes of minor AA 187 
genotype might be 2.5 fold more than those with common GG genotypes. However, our data 188 
revealed no changes in other biochemical parameters after the intervention. 189 
It is becoming evident that the individual response to a dietary program varies dependent on 190 
genetic factors 18. There is growing evidence that genetic factors are determinants of vitamin D 191 
status in different ethnic groups 19-22. Looking at potential determinants of 25(OH)D,  our group 192 
previously reported a significant difference among different genotypes of CYP1 SNP rs10766197 193 
in terms of responding  to high-dose of vitamin D supplementation;  the changes in serum 25 (OH) 194 
D were much more in individuals with common GG genotype; however, this intervention 195 
deteriorate inflammation status in the holder of this genotype 17. Similarly, a German study 196 
demonstrated an association between serum vitamin D and the rs10741657 SNP 12. Another study 197 
conducted on individuals with gestational diabetes mellitus suggested that both genetic 198 
susceptibility and uterine environment appeared to be involved in GDM13. Arabi et.al examined 199 
influences of 2 different doses of VitD supplementation in 218 overweight individuals in the 200 
elderly population (>60 years) in terms of skeletal measures. Accordingly, it seemed that in their 201 
study, the serum 25(OH)D at baseline was related to CYP2R variants; however, these variants did 202 
not affect response to vitamin D supplementation23. Bu et al. studied 49 SNPs in genes related to 203 
metabolism of Vitamin D in 156 healthy Caucasian subjects, after adjusting for potential 204 
confounders, they found that variants in the CYP2R1 and Gc genes appeared to modulate serum  205 
25(OH)D 24.  Nissen et.al demonstrated that variants in CYP2R1 and Gc genes might be associated 206 
with circulating VitD and those haplotypes might lead to lower serum vitamin D in 201 healthy 207 
Danish families 25.  208 
Conclusion: 209 
We found that although the rs10741657 on CYP2R1 gene was not associated with baseline serum 210 
25 (OH) D in healthy adolescent Iranian girls, it may modulate the response to high-dose vitamin 211 
D supplementation so that participants with a minor AA genotype showed a higher level of vitamin 212 
D concentration after supplementation.  213 
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Figure 1. Comparison of the vitamin D status categories before and after 9 weeks of vitamin D supplementation in the 317 
total population. Deficiency: Serum 25(OH)D level<50nmol/L. Sufficiency:  50nmol/L<Serum 25(OH)D 318 
level<75nmol/L. Proposed optimal>75nmol/L. 319 
 320 
 321 
 322 
 323 
Table 1.  Vitamin D status groups before and after 9 weeks of vitamin D supplementation according to CYP2R1-324 
rs10741657 genotypes. 325 
 326 
 327 
 328 
 329 
Table 2.  Comparisons of the variables before and after 9 weeks of vitamin D supplementation 330 
 331 
 332 
 333 
 334 
 335 
 336 
Fig.2.Serum 25(OH)D stratified by a polymorphism in the CYP1 gene. Values are means ± SD. Two-way ANCOVA 337 
repeated measures adjusted for multiple comparisons by Bonferroni test for serum 25(OH)D levels. Covariates used: 338 
age, gender, physical activity, smoking status. 339 
 340 
 341 
Table 3. Association of CYP2R1 gene rs10741657 variant with changes in serum vitamin D After 9 weeks 342 
supplementation (under different genetic models). 343 
Table 1.  Vitamin D status groups before and after 9 weeks of vitamin D supplementation according to CYP2R1-rs10741657 
genotypes. 
Vitamin D status 
(N=616) 
GG (N=269) AG (N=261) AA (N=86) 
Baseline Follow-up Baseline Follow-up Baseline Follow-up 
Proposed optimal 13 (4.8) 111 (53.9) 15 (5.7) 140 (63.3) 10 (11.6) 71 (82.7) 
Sufficiency 18 (6.7) 34 (16.5) 15 (5.7) 46 (20.8) 8 (9.3) 13(14.7) 
deficiency 238 (88.5) 61 (26.9) 231 (88.5) 35 (15.8) 68 (79.1) 2 (2.7) 
Note: Σ2 test showed a Ptrendof 0.1 at baseline; Ptrend at 9- week follow-up is <0.001 Data is presented as frequencies (%). Deficiency: 
Serum 25(OH)D level < 50 nmol/l. Sufficiency: Serum 25(OH) D level between 50 to 75 nmol/l. Proposed optimal: Serum 25(OH)D 
level > 75 nmol/l. 
 344 
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 360 
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Table 2.  Comparisons of the variables before and after 9 weeks of vitamin D supplementation  
Variable GG(n=269) AG(n=261) AA (n=87) 
Anthropometric 
BMI (kg/m2) 
Baseline 21.9±4.2 21.6±4.4 21.7±4 
After 9 weeks 21.7±4.2 21.6±4.4 21.5±4 
Change (%) -0.1±6.6 -0.2±5.1 -0.8±3.9 
WHR(cm) 
Baseline 0.8±0.07 0.8±0.07 0.8±0.07 
After 9 weeks 0.8±0.3 0.8±0.1 0.8±0.1 
Change (%) 1.9±4.1 -0.6±9.3 0.6±6.9 
SBP(mmHg) 
Baseline 101.2±12.1 101.3±13.1 99.1±12.6 
After 9 weeks 100.9±12.3 100.1±13.6 99.6±12.6 
Change (%) 0.2±13.1 -0.5±14 1.2±15 
DBP(mmHg) 
Baseline 68.4±9.7 66.9±11.4 66.5±9.8 
After 9 weeks 66.0±10.1 64.9±9.9 62.4±11.2 
Lipid profile 
 
Cholesterol(mg/dl) 
Baseline 165.3±28.2 162.6±28.4 162.1±26.8 
After 9 weeks 154.7±27.9 153.9±27 151.2±28.2 
Change (%) -5.2±19.6 -4.4±13.9 -3.9±14.1 
TG(mg/dl) 
Baseline 81.7±33.4 82.6±35.1 80.9±35.3 
After 9 weeks 77.7±33 81.1±32.0 73.5±28 
Change (%) -0.3±33 4.8±32.5 -1.05±31.4 
HDL(mg/dl) 
Baseline 48.2±9.1 45.4±8.4 45.5±7.3 
After 9 weeks 47.2±8.7 45.3±8.4 45.04±7 
Change (%) -3±14.3 -2.3±15 0.8±15.7 
LDL(mg/dl) 
Baseline 102.1±22.7 100.2±23.8 99.7±20.7 
After 9 weeks 92.6±20 91.2±32 90.0±24.4 
Change (%) -8.5±19 -7.2±20 -7±20.9 
FBS(mg/dl) 
Baseline 88.6±11.7 87.1±12 85.9±9.4 
After 9 weeks 87.1±12 86.8±11.6 83.9±10 
Change (%) -1.4±13 -1.4±12 -3.1±11.3 
Inflammatory measures 
WBC(109/L) 
Baseline 6.35±3.3 6.3±1.7 6.1±1.7 
After 9 weeks 5.7±1.5 6.07±1.4 5.9±1.5 
Change (%) -0.2±3.4 3.3±3 5.5±4.4 
Hs-CRP(mg/L) 
Baseline 1.4±1.7 1.47±1.9 1.6±2.1 
After 9 weeks 1.5±1.44 1.52±1.5 1.4±1.2 
Change (%) 0.9±2.6 1±2.9 0.6±1.9 
Serum electrolytes 
VitD*(nmol/L) 
Baseline 26.0±23.0 26.0±24.1 30.6±28.7 
After 9 weeks* 81.1±42.9 91.1±40.4 111.6±37.3 
Change (%)** 363.3±354.0 443.7±384.6 539.4±443.1 
Ca(mg/dL) 
Baseline 9.34±0.6 9.5±0.5 9.4±0.5 
After 9 weeks 9.6±0.5 9.7±0.5 9.7±o.4 
Change (%) 3.3±7.7 2.3±8 2.1±7 
Phosphorus(mg/dL) 
Baseline 3.91±0.4 3.9±0.4 3.8±0.4 
After 9 weeks 4.09±0.36 4.1±0.4 4.05±0.4 
Change (%) 5.3±11.3 5.3±9.8 6.2±11 
Creatinine(mg/dL) 
Baseline 0.6±0.1 0.6±0.09 0.65±0.09 
After 9 weeks 0.7±0.08 0.7±0.09 0.7±0.08 
Change (%) 13.3±38 9.6±14.2 8.9±14 
BUN(mg/dL) 
Baseline 12.09±3.04 12.6±3.02 12.1±2.7 
After 9 weeks 13.9±3.3 14.03±3.3 12.9±3.4 
Change (%) 29.8±143 22.1±12 11.1±32 
Note: Change = ((Follow up – Baseline)/Baseline)/100; Co-dominant genetic model (GG genotype vs. AG+AA 
genotypes); Dominant genetic model (GG+AG genotypes vs. AA genotype). *P value (GG vs AA/AG)<0.001, **P value 
(GG vs AA/AG)=0.003 
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Table 3. Association of CYP2R1 gene rs10741657 variant with changes in serum vitamin D 
After 9 weeks supplementation in Iranian population (under different genetic models). 
A
d
d
it
iv
e 
m
o
d
el
 GG AG AA 
Reference  
(Common genotype) 
 
OR (CI95%), p value OR (CI95%), p value 
1 1.7 (0.9-3), 0.05 2.5 (1.4-4.4), 0.002 
R
ec
es
si
v
e 
m
o
d
el
 
GG/AG AA 
Reference OR (CI95%), p value 
1 1.65 (1.1-2,4), 0.008 
D
o
m
in
an
t 
m
o
d
el
 
GG AA/AG 
Reference OR (CI95%), p value 
1 2.05 (1.2-3.4), 0.007 
Data was adjusted for age, BMI percentile, physical activity, passive smoking. 
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